Il ruolo della chemioterapia nel trattamento dell'osteosarcoma

Translated title of the contribution: Chemotherapy of osteosarcoma

S. Ferrari, G. Bacci

Research output: Contribution to journalArticle

Abstract

Chemotherapy and complete surgical removal of the tumor is the standard treatment for patients with osteosarcoma. Due to the rarity of the disease and to the reduced number of randomized clinical studies, standard chemotherapy combination is not defined yet. High dose methotrexate, cisplatin, doxorubicin and ifosfamide are the most effective, and more commonly used drugs for osteosarcoma. Non controlled clinical studies showed that the best oncologic results were achieved when all the four drugs were used, but these observations have not been confirmed by randomized clinical studies. Primary chemotherapy and delayed surgery followed by adjuvant chemotherapy is the strategy of treatment usually adopted, but there is no evidence that such strategy was better, in terms of disease-free survival, than immediate surgery and adjuvant chemotherapy. Since the histologic response to primary chemotherapy is a prognostic factor, in some trials the drugs used in the postoperative treatment were modified according to the primary chemotherapy induced tumor necrosis (salvage chemotherapy). There is no agreement on the effectiveness of this strategy of treatment. Standard treatment in patients with recurrent osteosarcoma is the surgical removal of recurrence. There is no agreement on the effectiveness of second-line chemotherapy, and also the use of high dose chemotherapy treatment and PBSC rescue showed disappointing results. Patients with metastatic osteosarcoma are treated with the same drugs used for localized patients, but their prognosis is worse even if they undergo complete surgery.

Original languageItalian
Pages (from-to)205-217
Number of pages13
JournalMinerva Ortopedica e Traumatologica
Volume53
Issue number4
Publication statusPublished - Aug 2002

Fingerprint

Osteosarcoma
Drug Therapy
Adjuvant Chemotherapy
Pharmaceutical Preparations
Therapeutics
Ifosfamide
Combination Drug Therapy
Methotrexate
Doxorubicin
Cisplatin
Disease-Free Survival
Neoplasms
Necrosis
Recurrence
Clinical Studies

ASJC Scopus subject areas

  • Surgery

Cite this

Il ruolo della chemioterapia nel trattamento dell'osteosarcoma. / Ferrari, S.; Bacci, G.

In: Minerva Ortopedica e Traumatologica, Vol. 53, No. 4, 08.2002, p. 205-217.

Research output: Contribution to journalArticle

Ferrari, S. ; Bacci, G. / Il ruolo della chemioterapia nel trattamento dell'osteosarcoma. In: Minerva Ortopedica e Traumatologica. 2002 ; Vol. 53, No. 4. pp. 205-217.
@article{578fd74c08f644dfb3e81fea37d6425a,
title = "Il ruolo della chemioterapia nel trattamento dell'osteosarcoma",
abstract = "Chemotherapy and complete surgical removal of the tumor is the standard treatment for patients with osteosarcoma. Due to the rarity of the disease and to the reduced number of randomized clinical studies, standard chemotherapy combination is not defined yet. High dose methotrexate, cisplatin, doxorubicin and ifosfamide are the most effective, and more commonly used drugs for osteosarcoma. Non controlled clinical studies showed that the best oncologic results were achieved when all the four drugs were used, but these observations have not been confirmed by randomized clinical studies. Primary chemotherapy and delayed surgery followed by adjuvant chemotherapy is the strategy of treatment usually adopted, but there is no evidence that such strategy was better, in terms of disease-free survival, than immediate surgery and adjuvant chemotherapy. Since the histologic response to primary chemotherapy is a prognostic factor, in some trials the drugs used in the postoperative treatment were modified according to the primary chemotherapy induced tumor necrosis (salvage chemotherapy). There is no agreement on the effectiveness of this strategy of treatment. Standard treatment in patients with recurrent osteosarcoma is the surgical removal of recurrence. There is no agreement on the effectiveness of second-line chemotherapy, and also the use of high dose chemotherapy treatment and PBSC rescue showed disappointing results. Patients with metastatic osteosarcoma are treated with the same drugs used for localized patients, but their prognosis is worse even if they undergo complete surgery.",
keywords = "Drug therapy, Osteosarcoma, surgery, Prognosis, Treatment outcome",
author = "S. Ferrari and G. Bacci",
year = "2002",
month = "8",
language = "Italian",
volume = "53",
pages = "205--217",
journal = "Minerva Ortopedica",
issn = "0026-4911",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "4",

}

TY - JOUR

T1 - Il ruolo della chemioterapia nel trattamento dell'osteosarcoma

AU - Ferrari, S.

AU - Bacci, G.

PY - 2002/8

Y1 - 2002/8

N2 - Chemotherapy and complete surgical removal of the tumor is the standard treatment for patients with osteosarcoma. Due to the rarity of the disease and to the reduced number of randomized clinical studies, standard chemotherapy combination is not defined yet. High dose methotrexate, cisplatin, doxorubicin and ifosfamide are the most effective, and more commonly used drugs for osteosarcoma. Non controlled clinical studies showed that the best oncologic results were achieved when all the four drugs were used, but these observations have not been confirmed by randomized clinical studies. Primary chemotherapy and delayed surgery followed by adjuvant chemotherapy is the strategy of treatment usually adopted, but there is no evidence that such strategy was better, in terms of disease-free survival, than immediate surgery and adjuvant chemotherapy. Since the histologic response to primary chemotherapy is a prognostic factor, in some trials the drugs used in the postoperative treatment were modified according to the primary chemotherapy induced tumor necrosis (salvage chemotherapy). There is no agreement on the effectiveness of this strategy of treatment. Standard treatment in patients with recurrent osteosarcoma is the surgical removal of recurrence. There is no agreement on the effectiveness of second-line chemotherapy, and also the use of high dose chemotherapy treatment and PBSC rescue showed disappointing results. Patients with metastatic osteosarcoma are treated with the same drugs used for localized patients, but their prognosis is worse even if they undergo complete surgery.

AB - Chemotherapy and complete surgical removal of the tumor is the standard treatment for patients with osteosarcoma. Due to the rarity of the disease and to the reduced number of randomized clinical studies, standard chemotherapy combination is not defined yet. High dose methotrexate, cisplatin, doxorubicin and ifosfamide are the most effective, and more commonly used drugs for osteosarcoma. Non controlled clinical studies showed that the best oncologic results were achieved when all the four drugs were used, but these observations have not been confirmed by randomized clinical studies. Primary chemotherapy and delayed surgery followed by adjuvant chemotherapy is the strategy of treatment usually adopted, but there is no evidence that such strategy was better, in terms of disease-free survival, than immediate surgery and adjuvant chemotherapy. Since the histologic response to primary chemotherapy is a prognostic factor, in some trials the drugs used in the postoperative treatment were modified according to the primary chemotherapy induced tumor necrosis (salvage chemotherapy). There is no agreement on the effectiveness of this strategy of treatment. Standard treatment in patients with recurrent osteosarcoma is the surgical removal of recurrence. There is no agreement on the effectiveness of second-line chemotherapy, and also the use of high dose chemotherapy treatment and PBSC rescue showed disappointing results. Patients with metastatic osteosarcoma are treated with the same drugs used for localized patients, but their prognosis is worse even if they undergo complete surgery.

KW - Drug therapy

KW - Osteosarcoma, surgery

KW - Prognosis

KW - Treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=0036707155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036707155&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0036707155

VL - 53

SP - 205

EP - 217

JO - Minerva Ortopedica

JF - Minerva Ortopedica

SN - 0026-4911

IS - 4

ER -